Incretin Regulation of Insulin Secretion in Monogenic Diabetes

University of Chicago10 enrolled

Overview

The purpose of this study is to explore the mechanisms of metabolic control in monogenic diabetes patients treated with sulfonylurea medications.

Monogenic diabetes patients and healthy matched controls will be admitted to the University of Chicago Clinical Resource Center for a total of 4 nights. The following will take place on separate days: 1. Oral Glucose Tolerance Test (OGTT): consume sugary drink and blood samples will be collected at multiple time points 2. Isoglycemic glucose infusion (IGI) test: glucose will be infused via a vein in the arm and and blood samples will be collected at multiple time points 3. OGTT during GLP-1 infusion 4. IGI during Exendin-9 infusion

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Monogenic Diabetes

Interventions

GLP-1DRUG

OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion

Exendin 9-39DRUG

OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion

Eligibility

Sex: ALLMin age: 18 YearsMax age: 89 YearsHealthy volunteers:

Medical Language ↔ Plain English

Monogenic Diabetes Subjects: Inclusion Criteria: * Diagnosis of monogenic diabetes * Previously participated in US Neonatal Diabetes Registry (IRB 15617B) or Genetics of diabetes mellitus (IRB 6858) * Age: 18 years + Exclusion Criteria: * Pregnancy * Acute medical illness or chronic conditions including: cardiac failure, renal insufficiency (estimated glomerular filtration rate \<50 ml/min), hepatic insufficiency (known cirrhosis or hepatitis), chronic obstructive pulmonary disease, gastrointestinal disorders causing malabsorption, anemia (Hct \< 36%), or uncontrolled hypertension Healthy Controls: Inclusion Criteria: * Good general health * Stable weight for 6 months * Age: 18 years + Exclusion Criteria: * Pregnancy * Acute medical illness or chronic conditions including: cardiac failure, renal insufficiency (estimated glomerular filtration rate \<50 ml/min), hepatic insufficiency (known cirrhosis or hepatitis), chronic obstructive pulmonary disease, gastrointestinal disorders causing malabsorption, anemia (Hct \< 36%), or uncontrolled hypertension

Locations (1)

University of Chicago

Chicago, Illinois, United States

Outcomes

Primary Outcomes

Incretin Effect

Directly calculated from the difference between oral and IV stimulated insulin secretion

Time frame: Baseline

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.